neuroClues Raises €10M for Eye-Tracking Parkinson's Diagnostics

neuroClues Raises €10M for Eye-Tracking Parkinson's Diagnostics

French-Belgian medtech company neuroClues has closed a Series A funding round of €10 million. This capital is intended to support the development and commercialization of its innovative diagnostic technology. The company focuses on creating advanced solutions for the early detection of neurodegenerative diseases, a critical area for improving clinical outcomes.

The core of neuroClues's offering is a portable eye-tracking headset, designed to identify oculomotor biomarkers. These indicators are crucial for diagnosing complex conditions such as Parkinson's, Alzheimer's, and multiple sclerosis, offering the possibility of intervention years before the onset of overt clinical symptoms. The company has already obtained CE certification in January 2025 and is working towards securing FDA clearance in the United States by 2026, with the goal of making its technology accessible to neurologists in both markets.

Innovation in Early Diagnostics and Technical Details

neuroClues positions itself at the forefront of early diagnosis for neurodegenerative diseases through a non-invasive and highly precise approach. Its device, a portable headset, is engineered to capture a high volume of data: up to 800 infrared images per eye per second. This high-frequency data acquisition capability is fundamental for detecting subtle variations in eye movements that can indicate the presence of neurological pathologies.

The analysis of these images allows for the extraction of extremely precise oculomotor biomarkers. These biomarkers represent key indicators for conditions such as Parkinson's, Alzheimer's, and multiple sclerosis. The most significant aspect of this technology is the ability to identify these signals years before clinical symptoms manifest, offering a crucial opportunity for timely therapeutic interventions and improved disease management, potentially slowing progression or enhancing patients' quality of life.

Implications for Data Sovereignty and Deployment

The processing of such sensitive medical data, like that collected by the neuroClues device, raises important questions regarding data sovereignty and regulatory compliance. In contexts such as Europe, GDPR imposes stringent requirements on the localization, protection, and management of personal and health data. This scenario prompts healthcare and research organizations to carefully evaluate their AI infrastructure deployment strategies.

For facilities adopting advanced diagnostic technologies, the choice between cloud and on-premise solutions becomes strategic. Local data processing (self-hosted or on-premise) or at the network edge (edge computing) can offer significant advantages in terms of direct data control, security, and compliance with stringent regulations. Although the source does not specify neuroClues's deployment architecture, the high volume of images per eye per second suggests the need for robust processing capabilities, which could benefit from dedicated infrastructure to ensure low latency and high throughput while maintaining maximum data protection. For those evaluating on-premise deployment for AI/LLM workloads, AI-RADAR offers analytical frameworks on /llm-onpremise to assess the trade-offs between cost, performance, and data sovereignty.

Future Prospects and Regulatory Recognitions

The €10 million Series A funding will enable neuroClues to accelerate the development and commercialization of its technology on an international scale. The company has already obtained CE certification in January 2025, a crucial step that allows it to operate and distribute its device in the European market. This regulatory recognition attests to the product's compliance with the European Union's safety and health standards.

The next and equally ambitious goal is to secure approval from the FDA (Food and Drug Administration) in the United States by 2026. These regulatory recognitions are vital for the widespread adoption of the device by neurologists in Europe and the United States. The ability to offer early and non-invasive diagnostics for neurodegenerative diseases represents a significant advancement, with the potential to drastically improve patients' quality of life and optimize treatment strategies globally.